Reply to a Rebuttal: Enoxaparin and Unfractionated Heparin in Acute Coronary Syndromes without ST-segment Elevation

Javier Borja; Pere Olivella

doi:10.1055/s-0037-1613327

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 88(05): 886-887
DOI: 10.1055/s-0037-1613327

Letters to the Editor

Schattauer GmbH

Reply to a Rebuttal: Enoxaparin and Unfractionated Heparin in Acute Coronary Syndromes without ST-segment Elevation

Javier Borja

¹Pharmacia Spain, S. A., Medical Department, Crta. De Rubi, 90-100, 08190 Sant Cugat del Valles, Barcelona, Spain

,

Pere Olivella

¹Pharmacia Spain, S. A., Medical Department, Crta. De Rubi, 90-100, 08190 Sant Cugat del Valles, Barcelona, Spain

› Author Affiliations

Abstract

Full Text

References

References
1 Borja J, Olivella P. Enoxaparin and unfractionated heparin in acute coronary syndromes without ST-segment elevation. Thromb Haemost 2002; 87: 538.
2 Antman EM, Mc Cabe CH, Gurfinkel EP, Turpie AGO, Berning PJLM, Salein DF, Bayes de Luna A, Fox K, Lablanche JM, Radley D, Premmereur J. for the TIMI 11 B Investigators. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the Thrombolisis in Myocardial Infarction (TIMI) 11 B Trial. Circulation 1999; 100: 1593-601.
3 Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Lamger A, Calif RM, Premmereur J, Bigonzi F. for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447-52.
4 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hoch-man JS, Jones RH, Kereikakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Theroux P. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segement elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000; 36: 970-1062.
5 Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hoch-man JS, Jones RH, Kereikakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith III EE, Steward DE, Theroux P. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segement elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). 2002 Available at: http://www.acc.org/clinical/guidelines/un-stable/unstable/unstable.pdf.
6 Antman E, Cohen M, Radley D, Mc Cabe C, Rush J, Premmereur J, Braunwald E. for the TIMI 11 B (thrombolisis in Myocardial Infarction) and ESSENCE (Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-wave Coronary Events) Investigators. Assessment of the treatment of enoxaparin for unstable angina/Non-Q-wave myocardial infarction. TIMI 11 B-ESSENCE meta-analysis. Circulation 1999; 100: 1602-8.
7 The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in acombination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
8 Ryan TJ, Antman EN, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith III E E, Weaver WD. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee of Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34: 890-911 Available at http://www.acc.org/clinical/guidelines
9 Michahs LK, Papamichael ND, Katsouras CS, Adamidis K, Sourla E, Novas J, Sioros L, Papalambrakopoulos A, Goudevenos JA, Sideris DA. Enoxaparin versus tinzaparin in unstable coronary syndromes. A head-to-head comparison (EVET trial). Eur Heart J 2001; 22 (Abstr. Suppl.) 2001; 664.
10 Michahs LK, Papamichail N, Katsouras CS, Karahaliou A, Sourta E, Novas J, Sioros L, Papalambrakopoulos A, Goudevenos JA, Sideris DA. Enoxaparin versus tinzaparin in the management of unstable coronary artery disease (EVET Study). J Am Coll Cardiol 2001; 37 (Suppl A): 365A.
11 Holdright D, Patel D, Cunningham D, Thomas R, Hubbard W, Hendry G, Sutton G. Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. J Am Coll Cardiol 1994; 24: 39-45.
12 Bertrand ME, Chair ML, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W. Recommendations of the Task Force of the European Society of Cardiology. Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation. Eur Heart J 2000; 21: 1406-32.
13 Oler A, Whooley M, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis. JAMA 1996; 276: 811-5.
14 Gurfinkel EP, Manos EJ, Mejail RI, Cerda MA, Duronto EA, Garcia CN, Daroca AM, Mautner B. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995; 26: 313-8.
15 Klein W, Buchwald A, Hillis SE, Monrad S, Sanz G, Turpie AGG, Van der Meer J, Olafson E, Undenland S, Ludwig K. for the FRIC investigators. Comparison of low-molecular-weight heparin wifli unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in Unstable Coronary Artery Disease Study (FRIC). Circulation 1997; 97: 61-8.
16 The FRAX.I.S. study Group. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6 day treatment of unfractionated heparin in the initial management of unstable angina or non-Q-wave myocardial infarction: FRAXIS (FRAXiparine in Ischaemic Syndrome). Eur Heart J 1999; 20: 1553-62.
17 Bozovich GE, Gurfinkel EP, Antman EM, McCabe CH, Mautner B. Superiority of enoxaparin versus unfractionated heparin for unstable angina/non-Q-wave myocardial infarction regardless of activated partial thromboplastin time. Am Heart J 2000; 140: 637-42.
18 Montalescot G, Collet JP, Lison L, Choussat R, Ankri A, Vicaut E, Perlemuter K, Philippe F, Drobinski G, Thomas D. Effects of various anticoagulant treatment on von Willebrand factor release in unstable angina. J Am Coll Cardiol 2000; 36: 110-4.
19 Hodl R, Huber K, Kraxner W, Nikfradjam M, Schumacher M, Fruhwald M F, Zorn G, Wonish M, Klein W. Comparison of effects of dalteparin and enoxaparin on hemostatic parameters and von Willebrand factor in patients with unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. Am J Cardiol 2002; 89: 589-92.